A personalized melanoma vaccine, called intismeran, could mark a major advance in cancer treatment. Last week, pharmaceutical ...

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of ...

Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared ...

Adding a personalised messenger RNA (mRNA) cancer vaccine to pembrolizumab — an immunotherapy drug — after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, phase III ...

A breakthrough vaccine treatment has been found in newly-published data to lower the risk of melanoma returning and cancer-related death by 42% when combined with standard treatment.

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 28, 2026 (HealthDay News) — A personalized cancer vaccine can ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is ...

The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach ...

By Michael Erman and Julie Steenhuysen Oct 22 (Reuters) - Moderna and Merck said on Thursday that their mRNA cancer vaccine ...

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for ...

Clinicians must weigh the urgency of cancer treatment against gestational age and coordinate treatment decisions with ...

According to a study published in the academic journal ‘Journal of Cosmetics, Dermatological Sciences and Applications’, ...